Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?

SE Engelen, AJB Robinson, YX Zurke… - Nature Reviews …, 2022 - nature.com
Atherosclerosis is a chronic inflammatory disease of the arterial wall, characterized by the
formation of plaques containing lipid, connective tissue and immune cells in the intima of …

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis

K Ghoreschi, A Balato, C Enerbäck, R Sabat - The Lancet, 2021 - thelancet.com
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

Pathophysiology, clinical presentation, and treatment of psoriasis: a review

AW Armstrong, C Read - Jama, 2020 - jamanetwork.com
Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Neuromodulation by the immune system: a focus on cytokines

AF Salvador, KA de Lima, J Kipnis - Nature Reviews Immunology, 2021 - nature.com
Interactions between the immune system and the nervous system have been described
mostly in the context of diseases. More recent studies have begun to reveal how certain …

[HTML][HTML] Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

Y Zhang, V Chandra, E Riquelme Sanchez… - Journal of experimental …, 2020 - rupress.org
Disclosure: Dr. Maitra reports Thrive Earlier Detection has licensed an invention from Johns
Hopkins University in which Dr. Maitra is listed as an inventor. The focus of the license is on …

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind …

K Reich, KA Papp, A Blauvelt, RG Langley… - The Lancet, 2021 - thelancet.com
Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double …

BG Feagan, BE Sands, WJ Sandborn… - The Lancet …, 2023 - thelancet.com
Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

The role of helper T cells in psoriasis

P Hu, M Wang, H Gao, A Zheng, J Li, D Mu… - Frontiers in …, 2021 - frontiersin.org
Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis

M Furue - International journal of molecular sciences, 2020 - mdpi.com
Atopic dermatitis (AD) is an eczematous, pruritic skin disorder with extensive barrier
dysfunction and elevated interleukin (IL)-4 and IL-13 signatures. The barrier dysfunction …

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

JA Singh, G Guyatt, A Ogdie… - Journal of Psoriasis …, 2019 - journals.sagepub.com
Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …